NCT00171574

Antiproteinuric Effect of Valsartan and Lisinopril

Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 124 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: —

Summary

Title: Antiproteinuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), double blind, parallel group, controlled trial, 5 months follow-up. Objective: To evaluate the antiproteinuric effect of high doses of valsartan vs combo treatment in no-diabetic and diabetic patients. Hypothesis: Combo treatment reduces microalbuminuria, proteinuria and the albumin/creatinin ratio more than monotherapies. Design: Multicentric, randomized, double blind, parallel group, active controlled. Dose / regimen Valsartan 320 vs Lisinopril 40 vs Valsartan/lisinopril 160/20

Conditions

• Hypertension
• Diabetic Nephropathy

Interventions

Type	Name	Description
DRUG	Valsartan
DRUG	Valsartan plus HCTZ
DRUG	Lisinopril

Timeline

• Start date: 2004-11-01
• Primary completion: 2006-07-01
• Completion: 2006-07-01
• First posted: 2005-09-15
• Last updated: 2017-02-24

Locations

1 site across 1 country: Switzerland